ID: ALA38545

Max Phase: Preclinical

Molecular Formula: C32H33ClN2O3S2

Molecular Weight: 593.21

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3nc4ccccc4s3)cc12

Standard InChI:  InChI=1S/C32H33ClN2O3S2/c1-31(2,3)40-29-23-16-22(38-19-28-34-24-8-6-7-9-27(24)39-28)14-15-25(23)35(18-20-10-12-21(33)13-11-20)26(29)17-32(4,5)30(36)37/h6-16H,17-19H2,1-5H3,(H,36,37)

Standard InChI Key:  YHWPKGLIJNVARR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 593.21

Molecular Weight (Monoisotopic): 592.1621

AlogP: 9.08

#Rotatable Bonds: 9

Polar Surface Area: 64.35

Molecular Species: ACID

HBA: 6

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.27

CX Basic pKa: 1.32

CX LogP: 8.72

CX LogD: 5.74

Aromatic Rings: 5

Heavy Atoms: 40

QED Weighted: 0.17

Np Likeness Score: -1.00

References

1. Woods KW, Brooks CD, Maki RG, Rodriques KE, Bouska JB, Young P, Bell RL, Carter GW.  (1996)  O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors,  6  (13): [10.1016/S0960-894X(96)00271-5]

2. Frenette R, Hutchinson JH, Léger S, Thérien M, Brideau C, Chan CC, Charleson S, Ethier D, Guay J, Jones TR, McAuliffe M, Piechuta H, Riendeau D, Tagari P, Girard Y..  (1999)  Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.,  9  (16): [PMID:10476875] [10.1016/s0960-894x(99)00399-6]

Source

Source(1):

• Scientific Literature